Phase II study of vinorelbine and ifosfamide in anthtracycline resistent metastatic breast cancer

P. Pronzato, P. Queirolo, M. Landucci, F. Vaira, A. Vigani, M. Gipponi, F. Cafiero

Research output: Contribution to journalArticlepeer-review

Abstract

The new combination of ifosfamide and vinorelbine was evaluated in a phase II study of patients with metastatic breast cancer. All the patients had evaluable or measurable lesions resistant to the combination of cyclophosphamide, epidoxorubicin and 5-fluorouracil. Out of 25 patients entered the trial, 7 achieved an objective response (28%) (95% C.I. 12-49.3). Ten patients (40%) experienced stable disease and the remaining patients (30%) progressive disease. The median time to progression was 4 months (range 2-12 +). The activity of the ifosfamide-vinorelbine combination has been demonstrated and the toxicity was acceptable.

Original languageEnglish
Pages (from-to)183-186
Number of pages4
JournalBreast Cancer Research and Treatment
Volume42
Issue number2
DOIs
Publication statusPublished - 1997

Keywords

  • Ifosfamide
  • Metastatic breast cancer
  • Second line chemotherapy
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Phase II study of vinorelbine and ifosfamide in anthtracycline resistent metastatic breast cancer'. Together they form a unique fingerprint.

Cite this